William Blair Reiterates Market Perform Rating on Moderna (MRNA) 'Competition in the space and waning vaccine sentiment are negatively impacting the base business'
Tweet Send to a Friend
William Blair analyst Myles Minter reiterated a Market Perform rating on Moderna (NASDAQ: MRNA)The analyst commented, "Phase III results from ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
